Aclaris Therapeutics, Inc. ACRS
NASDAQ
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -9.09% | -18.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -9.09% | -18.39% | |||
| Cost of Revenue | -10.92% | 11.89% | |||
| Gross Profit | 11.09% | -15.80% | |||
| SG&A Expenses | -0.17% | -10.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.38% | 5.70% | |||
| Operating Income | 8.33% | -7.87% | |||
| Income Before Tax | 13.93% | -8.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.93% | -8.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.93% | -8.48% | |||
| EBIT | 8.33% | -7.87% | |||
| EBITDA | -- | -7.87% | |||
| EPS Basic | 17.78% | 2.08% | |||
| Normalized Basic EPS | 13.99% | 3.43% | |||
| EPS Diluted | 17.78% | 2.08% | |||
| Normalized Diluted EPS | 13.99% | 3.43% | |||
| Average Basic Shares Outstanding | 4.70% | 10.81% | |||
| Average Diluted Shares Outstanding | 4.70% | 10.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||